Hailong R. Hu

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications

Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.

Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.

Journal: Frontiers in immunology
Published: July 06, 2026

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Journal: JCO oncology practice
Published: March 26, 2026

Chinese expert consensus on precision diagnosis and treatment of refractory tumors.

Chinese expert consensus on precision diagnosis and treatment of refractory tumors.

Journal: Critical reviews in oncology/hematology
Published: October 29, 2025

Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.

Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.

Journal: Frontiers in urology
Published: September 25, 2025

Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.

Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.

Journal: Cancer
Published: September 18, 2025

Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.

Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.

Journal: Cancer science
Published: September 08, 2025

A novel assistive device for enhancing extracorporeal shockwave lithotripsy in obese patients with distal ureteral stones.

A novel assistive device for enhancing extracorporeal shockwave lithotripsy in obese patients with distal ureteral stones.

Journal: BMC urology
Published: September 05, 2025

Analysis of the diagnostic value of peripheral blood immune inflammatory indicators of female bladder pain syndrome.

Analysis of the diagnostic value of peripheral blood immune inflammatory indicators of female bladder pain syndrome.

Journal: Frontiers in surgery
Published: August 15, 2025

Elevated C-reactive protein and D-dimer to predict venous thromboembolism in patients with bladder cancer.

Elevated C-reactive protein and D-dimer to predict venous thromboembolism in patients with bladder cancer.

Journal: Frontiers in immunology
Published: June 23, 2025

Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.

Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.

Journal: Therapeutic advances in medical oncology
Published: May 31, 2025

E2F transcription factors as multimodal biomarkers for pan-cancer management.

E2F transcription factors as multimodal biomarkers for pan-cancer management.

Journal: Scientific reports
Published: May 24, 2025

Senescence-associated signature based on immunotherapy response sequencing reveals PPIL3 as target for bladder cancer treatment and prognosis prediction.

Senescence-associated signature based on immunotherapy response sequencing reveals PPIL3 as target for bladder cancer treatment and prognosis prediction.

Journal: Frontiers in immunology
Published: April 16, 2025
Showing 1-12 of 92

Last Updated: 09/26/2026